Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.12355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.
Small
January 2025
Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.
Vancomycin (VAN) and daptomycin (DAP) are among the last-resort antibiotics for treating multidrug-resistant Gram-positive bacterial infections. They are administered intravenously (IV); however, ≈5 - 10% of the total IV dose is released in the gastrointestinal (GI) tract via biliary excretion, driving resistance emergence in commensal Enterococcus faecium (E. faecium) populations.
View Article and Find Full Text PDFThe effect of sevelamer on serum calcification propensity in patients with chronic kidney disease: the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial.
Clin Kidney J
January 2025
MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
Background: The serum calcification propensity test (or T50 test) might become a standard tool for the assessment of vascular calcification risk and T50 might be a valuable biomarker in clinical trials of treatments intended to slow the progression of vascular calcification. Literature data suggest that non-calcium-containing phosphate binders can influence T50 in chronic dialysed patients. However, it is not clear whether similar interventions are effective in patients at earlier stages of chronic kidney disease (CKD).
View Article and Find Full Text PDFEffectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies.
Nefrologia (Engl Ed)
December 2024
Department of Medical Doctor Study Program, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia.
Background: Chronic kidney disease (CKD) is a major global health problem. Hyperphosphatemia is frequent in CKD and a reason for increased morbidity and mortality as it generates hyperparathyroidism, high fibroblast growth factor 23 (FGF23), and hypocalcemia. Available hyperphosphatemia therapies still have limitations, including risk of metal overload, cardiovascular calcification, and systemic adverse effects (AEs).
View Article and Find Full Text PDFUpdate on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease.
Expert Opin Pharmacother
January 2025
Department of Nephrology and Dialysis, Past Director, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy.
Introduction: Hyperphosphatemia in advanced CKD often accompanies high PTH and FGF23 levels, impaired bone mineralization, ectopic calcifications, and increased cardiovascular risks. Novel treatments are now available to lower serum phosphorus effectively. However, safety, tolerability, and patient adherence must be evaluated to determine the best therapeutic option for hyperphosphatemia.
View Article and Find Full Text PDFTransarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer.
J Vasc Interv Radiol
February 2025
Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China; Institute for Advanced Study, Nanchang University, Nanchang, China. Electronic address:
Purpose: To determine how low inorganic phosphate stress (LIPS) induced by sevelamer particle transarterial embolization (S-TAE) affects immune regulation and angiogenesis in hepatocellular carcinoma.
Material And Methods: Transcatheter arterial embolization (TAE) using conventional ethiodized oil plus polyvinyl alcohol microspheres and S-TAE, which depletes intratumoral inorganic phosphate, were conducted on a McA-RH7777 orthotopic liver tumor model in rats, followed by the assessment of alterations in immunity-related and angiogenesis-related factors. The cells were cultured under hypoxic conditions and stimulated with LIPS to analyze the modulation of programmed cell death 1 ligand (PD-L1), vascular endothelial growth factor (VEGF)-α, and transforming growth factor-β1 expression using western blotting, quantitative real-time polymerase chain reaction, and immunofluorescence assays.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!